Moleculin Biotech, Inc. (MBRX) IPO - S-1 Filing, Stock & Insider Activity
Moleculin Biotech, Inc. IPO - Status & S-1 Filing
- Ticker: MBRX
- Status: Registered - S-1 filed with the SEC
- S-1 filed: 2026-07-29
- Exchange: NASDAQ
- Expected price range: not yet disclosed (set in a later S-1/A or pricing amendment)
- Shares offered: 4,566,210
- SEC CIK: 0001659617 · View the S-1 on SEC EDGAR →
Track every registration update on the InsiderAlpha IPO tracker.
Last SEC filing
Moleculin Biotech, Inc. (MBRX) has filed 3 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-25. 12 Form 8-K material event filings were reported by MBRX in the last 90 days. InsiderAlpha tracks every MBRX SEC filing - Form 4, Form 144, and 8-K - in real time, including Rule 10b5-1 plan detection.
About Moleculin Biotech, Inc. (MBRX)
Moleculin Biotech, Inc. trades under the ticker MBRX. InsiderAlpha tracks 23 primary SEC Form 4 filings from 8 reporting insiders for MBRX since 2024, sourced directly from SEC EDGAR.
| SEC CIK | 0001659617 |
|---|
90-Day SEC Filing Activity
| Form 4 filings (90d) | 3 |
|---|---|
| Form 8-K filings (90d) | 12 |
| Latest Form 4 filing | 2026-06-25 |
Recent MBRX Insider Transactions (Form 4)
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Donald H. Picker | Chief Science Officer | M - Option exercise | 71 | - | - | SEC | |
| Jonathan P. Foster | Chief Financial Officer | F - Tax withholding / forfeiture | 41 | $3.12 | $128 | SEC | |
| Jonathan P. Foster | Chief Financial Officer | M - Option exercise | 174 | - | - | SEC | |
| Walter V. Klemp | CEO and President | F - Tax withholding / forfeiture | 88 | $3.12 | $275 | SEC | |
| Walter V. Klemp | CEO and President | M - Option exercise | 360 | - | - | SEC | |
| Donald H. Picker | Chief Science Officer | F - Tax withholding / forfeiture | 21 | $3.12 | $66 | SEC | |
| Donald H. Picker | Chief Science Officer | F - Tax withholding / forfeiture | 13 | $2.88 | $37 | SEC | |
| Donald H. Picker | Chief Science Officer | M - Option exercise | 44 | - | - | SEC | |
| Walter V. Klemp | CEO and President | M - Option exercise | 150 | - | - | SEC | |
| Walter V. Klemp | CEO and President | F - Tax withholding / forfeiture | 37 | $2.88 | $107 | SEC | |
| Jonathan P. Foster | Chief Financial Officer | M - Option exercise | 109 | - | - | SEC | |
| Jonathan P. Foster | Chief Financial Officer | F - Tax withholding / forfeiture | 31 | $2.88 | $89 | SEC | |
| Donald H. Picker | Chief Science Officer | M - Option exercise | 8.8K | - | - | SEC | |
| Walter V. Klemp | CEO and President | F - Tax withholding / forfeiture | 7.0K | $0.50 | $3K | SEC | |
| Walter V. Klemp | CEO and President | M - Option exercise | 28.8K | - | - | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Moleculin Biotech, Inc. (MBRX). Updated in real time as new filings are submitted to the SEC.
Most-Active MBRX Insiders - Last 90 Days
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Jonathan P. Foster | 6 | $217 |
| Walter V. Klemp | 6 | $381 |
| Donald H. Picker | 6 | $103 |
Recent MBRX Form 8-K Material Events
- - Item 1.01, 9.01 [SEC]
- - Item 7.01, 9.01 [SEC]
- - Item 7.01, 9.01 [SEC]
- - Item 7.01, 9.01 [SEC]
- - Item 7.01, 9.01 [SEC]
Recent Insider Filings
- - Donald H. Picker (Chief Science Officer)
- - Walter V. Klemp (CEO and President)
- - Jonathan P. Foster (Chief Financial Officer)
- - Elizabeth Cermak (Director)
- - Michael D. Cannon (Director)
Form 4 Transaction Code Reference
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in MBRX insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
MBRX Insider Trading - FAQ
- What is the latest insider trade for MBRX?
- Moleculin Biotech, Inc. (MBRX) had 3 insider filings in the last 90 days, with the most recent on 2026-06-25. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
- How many insiders are buying MBRX stock?
- 0 insider purchases of MBRX were filed in the last 90 days.
- How many insiders are selling MBRX stock?
- 0 insider sales of MBRX were filed in the last 90 days.
- Where can I see MBRX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
- This page tracks MBRX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Companies with Insider Activity
Other companies in the InsiderAlpha index with a significant SEC Form 4 insider-trading footprint:
- $MCAH Mountain Crest Acquisition 6 Corp.
- $MDAT Web3Labs Global Inc.
- $MDKR Medikra Inc.
- $MDLN Medline Inc.
- $MESO MESOBLAST LTD
- $MEVO M Evo Global Acquisition Corp II
- $MFM ABERDEEN MUNICIPAL INCOME FUND
- $MGAM Mobile Global Esports, Inc.
- $MGN Megan Holdings Ltd.
- $MIAC Meridian3 Industrials Acquisition Corp
Learn More
- What is SEC Form 4?
- How to read insider buying signals
- Rule 10b5-1 trading plans explained
- The cluster buying signal
Open the live MBRX dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.